Padmasini Kumar

Immunology and Microbiology · Life Sciences

20h-index2.0kcitations33works2.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(10), RNA Interference and Gene Delivery(9), Cancer Research and Treatments(8), S100 Proteins and Annexins(6), Cancer Immunotherapy and Biomarkers(4)

Publications33 total

Pro-Angiogenic Role of Zinc Oxide in Wound Healing: Exploring thePotential of Zinc Supplementation for Enhanced Repair
Journal of Translational Research in Life Sciences·2025· 2 citedOpen Access
Assessment of Low Dose Vigil® Engineered Autologous Tumor Cell (EATC) Immunotherapy in Patients with Advanced Solid Tumors
Clinics in Oncology·2017· 3 cited
Preclinical Biodistribution and Safety Evaluation of a pbi-shRNA STMN1 Lipoplex after Subcutaneous Delivery
Toxicological Sciences·2016· 10 citedOpen Access
Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer
Gynecologic Oncology·2016· 88 cited
Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma
Molecular Therapy·2016· 42 citedOpen Access
Follow-up of bi-shRNA furin / GM-CSF Engineered Autologous Tumor Cell (EATC) Immunotherapy Vigil® in patients with advanced melanoma
Biomedical Genetics and Genomics·2016· 11 citedOpen Access
Pilot trial of vigil immunotherapy in Ewing’s sarcoma.
Journal of Clinical Oncology·2015· 4 cited
Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma
Molecular Therapy·2015· 53 citedOpen Access
Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer
Molecular Therapy·2015· 20 citedOpen Access
Survival effect of bi-shRNA<sup>furin</sup>/GMCSF DNA-based immunotherapy (FANG) in 123 advanced cancer patients to α-interferon-ELISPTOT response.
Journal of Clinical Oncology·2014· 2 cited
Vertically integrated translational studies of PDX1 as a therapeutic target for pancreatic cancer via a novel bifunctional RNAi platform
Cancer Gene Therapy·2014· 22 citedOpen Access
Summary of bi-shRNA&lt;sup&gt;furin&lt;/sup&gt;/GM-CSF Augmented Autologous Tumor Cell Immunotherapy (FANG™) in Advanced Cancer of the Liver
Oncology·2014· 49 cited
Assessment of intravenous pbi-shRNA PDX1 nanoparticle (OFHIRNA-PDX1) in yucatan swine
Cancer Gene Therapy·2013· 8 citedOpen Access
Immune response and survival of refractory cancer patients who received TGF-β2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccine
Gene Therapy·2013· 7 citedOpen Access
Bifunctional Short Hairpin RNA (bi-shRNA): Design and Pathway to Clinical Application
Methods in molecular biology·2012· 17 cited
Phase I Trial of “bi-shRNAifurin/GMCSF DNA/Autologous Tumor Cell” Vaccine (FANG) in Advanced Cancer
Molecular Therapy·2011· 193 citedOpen Access
<i>In vivo</i> Safety and Antitumor Efficacy of Bifunctional Small Hairpin RNAs Specific for the Human Stathmin 1 Oncoprotein
DNA and Cell Biology·2011· 40 cited
Phase I Trial of TGF-β2 Antisense GM-CSF Gene-Modified Autologous Tumor Cell (TAG) Vaccine
Clinical Cancer Research·2011· 54 cited
Enhanced target gene knockdown by a bifunctional shRNA: a novel approach of RNA interference
Cancer Gene Therapy·2010· 47 cited
FANG Vaccine: Autologous Tumor Cell Vaccine Genetically Modified to Express GM-CSF and Block Production of Furin
BioProcessing Journal·2010· 32 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

John Nemunaitis(23), Neil Senzer(23), Beena O. Pappen(15), Phillip B. Maples(13), Minal Barve(11), Donald D. Rao(9), Joseph A. Kuhn(7), Chris Jay(7), Zhaohui Wang(6), Gladice Wallraven(6), H. Anne Pereira(6), Gladice Wallraven(5), Alex Tong(4), Mitchell J. Magee(4), Jonathan Oh(4), Cynthia Bedell(4), Yang Yu(4), Paula Grammas(4), Daniel L. Shawler(3), Habib Fakhrai(3)